NCT01712425View on ClinicalTrials.gov

Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
HIV
Interventions
BIOLOGICAL

0-24 week prime/boost regimen

ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly

BIOLOGICAL

0-8 week prime/boost regimen

ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly

Trial Locations (2)

08916

Germans Trias i Pujol Hospital, Badalona

08036

Clinic de Barcelona Hospital, Barcelona

All Listed Sponsors
collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

HIVACAT

UNKNOWN

collaborator

University of Oxford

OTHER

lead

IrsiCaixa

OTHER

NCT01712425 - Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals | Biotech Hunter | Biotech Hunter